






# PHARMACEUTICAL 2020

## Nexien Biopharma INC Rank 363 of 363

The relative strengths and weaknesses of Nexien Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nexien Biopharma INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 0.000000000000082% points. The greatest weakness of Nexien Biopharma INC is the variable Assets, reducing the Economic Capital Ratio by 141% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.000000000000089%, being 238% points below the market average of 238%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 311                  |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 45                   |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 0                    |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 568                  |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 0                    |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 0                    |
| Research and Development                    | 64                   |
| Selling, General and Administrative Expense | 3,669                |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 311                  |
| Liabilities                 | 45                   |
| Expenses                    | 4,301                |
| Revenues                    | 0                    |
| Stockholders Equity         | 266                  |
| Net Income                  | -4,301               |
| Comprehensive Net Income    | -4,301               |
| BaseVar                     | 2,328                |
| ECR before LimitedLiability | -2,094%              |
| Economic Capital Ratio      | 0.000000000000082%   |